BMC Pediatr

1. JARSO H, Yohannes D, Gebru T, Kebebe L, et al
   Incomplete vaccination among children aged 12-35 months in West Arsi Zone, Ethiopia.
   BMC Pediatr. 2026 May 22. doi: 10.1186/s12887-026-07020.
   

   >> Share

   
   

   
   BMJ

2. BARANIUK C
   Ebola: WHO declares emergency as strain with no vaccine kills 100 in DRC and Uganda.
   BMJ. 2026;393:e313572.
   

   >> Share

   
   

   
   J Infect

3. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   

   >> Share

   
   
4. HUTTON MM, Vink PE, Kuxhausen A, Tsang M, et al
   Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients.
   J Infect. 2026 May 14:106758. doi: 10.1016/j.jinf.2026.106758.
   

   >> Share

   
   

   
   J Infect Dis

5. MUELLER BROWN K, Kindsvogel AM, Petnuch SE, Freeman TL, et al
   Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.
   J Infect Dis. 2026 May 15:jiag266. doi: 10.1093.
   

   >> Share

   
   

   
   J Virol

6. ZHOU C, Cheng M-L, He M-J, Liu Y, et al
   MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.
   J Virol. 2026 May 15:e0020826. doi: 10.1128/jvi.00208.
   

   >> Share

   
   
7. NASIR A, Lee D, Avena LE, Berrueta DM, et al
   Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
   J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
   

   >> Share

   
   
8. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   

   >> Share

   
   

   
   N Engl J Med

9. O'LEARY ST, Danchin M
   Childhood Vaccine Hesitancy.
   N Engl J Med. 2026 May 20. doi: 10.1056/NEJMcp2516616.
   

   >> Share

   
   

   
   Nat Immunol

10. PECETTA S, Andreano E, Rappuoli R
    Broadly protective mucosal vaccination in the respiratory tract.
    Nat Immunol. 2026 May 19. doi: 10.1038/s41590-026-02530.
    

    >> Share

    
    

    
    Nat Med

11. KIM JH, Ndembi N
    Global vaccine development.
    Nat Med. 2026;32:1610-1622.
    

    >> Share

    
    
12. CANFELL K
    HPV vaccines, 20 years on.
    Nat Med. 2026;32:1583-1585.
    

    >> Share

    
    

    
    PLoS One

13. MUBANGA C, Mubanga M, Chilyabanyama ON, Phiri M, et al
    Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX.
    PLoS One. 2026;21:e0335327.
    

    >> Share

    
    
14. PALOMBO CNT, Souza EA, Garcia EM, da Silva Araujo RP, et al
    Vaccine confidence and hesitancy among mothers of children under six years of age in Salvador, Brazil: The role of sociodemographic factors and health service experience.
    PLoS One. 2026;21:e0344742.
    

    >> Share

    
    
15. VISKUPIC F, Daly R, Wiltse DL, Gonda M, et al
    The relationship between personal COVID-19 vaccination decisions and cattle vaccination practices: Evidence from a survey of South Dakota beef producers.
    PLoS One. 2026;21:e0349234.
    

    >> Share

    
    
16. RIOS MONTOYA V, Suarez Alarcon AY, Perez Castillo S, Zamudio Raez T, et al
    Beyond coverage: Can vaccination reduce child mortality despite structural inequality? A global ecological analysis of routine childhood immunization (2010-2023).
    PLoS One. 2026;21:e0340756.
    

    >> Share

    
    
17. ESSAYAGH T, Essayagh M, Slibani H, El Hachimi S, et al
    Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study.
    PLoS One. 2026;21:e0347783.
    

    >> Share

    
    
18. 
    Retraction: SARS-CoV2 mRNA vaccine intravenous administration induces myocarditis in chronic inflammation.
    PLoS One. 2026;21:e0349831.
    

    >> Share

    
    
19. HURTADO-SALGADO E, Lazcano-Ponce E, Romero-Martinez M, Terrazas-Medina EA, et al
    Knowledge, attitudes, and practices related to adult vaccination among adults and healthcare professionals across Mexico.
    PLoS One. 2026;21:e0348625.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

20. ZHANG J, Zhang X, Yao Y, Zhou J, et al
    Multivalent mRNA vaccine platform with compatible antigens conferred broad-spectrum protection against orthoebolaviruses' exposure.
    Proc Natl Acad Sci U S A. 2026;123:e2517814123.
    

    >> Share

    
    
21. XIAO Z, Xu H, Ma N, Lei L, et al
    A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade.
    Proc Natl Acad Sci U S A. 2026;123:e2531588123.
    

    >> Share

    
    
22. DOOKIE R, Narciso AR, Gaytan MO, Narayana Moorthy A, et al
    Pneumococcal membrane particles promote serotype-independent cellular and humoral immunity and protect against pneumococcal colonization.
    Proc Natl Acad Sci U S A. 2026;123:e2537226123.
    

    >> Share

    
    

    
    Science

23. KUPFERSCHMIDT K
    Scientists play catch-up to startling Ebola outbreak.
    Science. 2026;392:792-793.
    

    >> Share

    
    

    
    Vaccine

24. RANQUE B, Galtier F, Nunes H, Le Jeunne C, et al
    Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.
    Vaccine. 2026;86:128732.
    

    >> Share

    
    
25. HARMA V, Palsola M, Kuusipalo A, Lindh E, et al
    Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry.
    Vaccine. 2026;86:128736.
    

    >> Share

    
    
26. TANG Q, Li J, Hou C, Qiu Z, et al
    Optimization of chicory root polysaccharide liposomes and their adjuvant efficacy in Newcastle disease vaccination.
    Vaccine. 2026;86:128734.
    

    >> Share

    
    
27. HURST DJ, Bobier CA, Coleman M, Streeks-Wooden N, et al
    Presumptive recommendations and informed consent in pediatric vaccination.
    Vaccine. 2026;86:128747.
    

    >> Share

    
    
28. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    

    >> Share

    
    
29. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    

    >> Share

    
    
30. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    

    >> Share

    
    
31. CABURNAY CA, Fu QJ, Carter T, Butler T, et al
    Identification of best outreach strategies and delivery modalities for population subgroups for COVID-19 vaccination.
    Vaccine. 2026;60 Suppl 1:128721.
    

    >> Share

    
    
32. MALHOTRA G, Bilguche A, Eades O, Loftus MJ, et al
    Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.
    Vaccine. 2026;86:128735.
    

    >> Share

    
    
33. BETTINA H, Anna SJ, Reinhard K
    A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1).
    Vaccine. 2026;86:128729.
    

    >> Share

    
    
34. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    

    >> Share

    
    
35. ISHOSO DK, Fandema E, Hoff NA, Nkamba DM, et al
    Dropout from the pentavalent vaccine series among children aged 12-23 months in the Central African Republic: prevalence, associated factors, and caregiver-reported barriers.
    Vaccine. 2026;85:128700.
    

    >> Share

    
    
36. CHEN M, Zhang X, Yao Y, Yu J, et al
    Complete protection against lethal Nipah virus challenge by intranasal vaccination with bacteriophage T4 coupled with Nipah virus G or F protein.
    Vaccine. 2026;85:128727.
    

    >> Share

    
    
37. SUN X, Liu R, Yang H, Zhang Y, et al
    A nanoparticle vaccine targeting glycoprotein D induces immune protection against pseudorabies virus.
    Vaccine. 2026;85:128704.
    

    >> Share

    
    
38. CAO T, Chen B, Chen S, Liu H, et al
    Instruments for measuring parents' vaccine hesitancy towards their children based on the COSMIN guidelines: A systematic review.
    Vaccine. 2026;85:128703.
    

    >> Share

    
    
39. NUWAGABA-BIRIBONWOHA H, Lamb MR, Dlamini X, Zerbe A, et al
    Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini.
    Vaccine. 2026;85:128692.
    

    >> Share

    
    
40. ZENG L, Pan D, Huang Y, Luo D, et al
    Double proline- substituted porcine epidemic diarrhea virus full-length spike mRNA vaccine confers enhanced immunogenicity and protective efficacy compared to conventional inactivated vaccine.
    Vaccine. 2026;85:128699.
    

    >> Share

    
    
41. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    

    >> Share

    
    
42. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    

    >> Share

    
    
43. WILSON LF, Dobson AJ, Mishra GD
    Associations between childhood adversity and human papillomavirus vaccination in Australian women: a cross-sectional study.
    Vaccine. 2026;85:128719.
    

    >> Share

    
    
44. SHAPIRO I, Tadese BK, Hoshen M, Chen YT, et al
    Corrigendum to "A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel" [Vaccine 80 (2029) 128516].
    Vaccine. 2026;85:128695.
    

    >> Share

    
    

    
    Virology

45. BEHNEZHAD F, Ataei-Pirkooh A, Kachooei A, Golsaz-Shirazi F, et al
    The rotavirus cVLP(VP8 *) vaccine candidate induces cross-genotype/heterotypic neutralizing antibody responses against human rotavirus G9P[4].
    Virology. 2026;621:110957.
    

    >> Share

    
    

    
    Virus Res

46. VALENZUELA-FUENZALIDA JJ, Velarezco LM, Silva V, Delgado F, et al
    Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Virus Res. 2026 May 20:199748. doi: 10.1016/j.virusres.2026.199748.
    

    >> Share

    
    
47. AGGAD WS, Mishra SK, Alqahtani T, Guendouzi A, et al
    Epitope-based vaccine of NiV targeting glycoprotein and fusion protein: an integrated immunoinformatics and bioinformatics approach.
    Virus Res. 2026;369:199746.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share